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Available online 18 August 2016Background: Response to diseasemodifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often
heterogeneous.We aimed to identify types of disease activity trajectories following the initiation of a newbiolog-
ic DMARD (bDMARD).
Methods: Pooled analysis of nine national registries of patients with diagnosis of RA, who initiated Abatacept and
had at least twomeasures of disease activity (DAS28).We used growthmixture models to identify groups of pa-
tients with similar courses of treatment response, and examined these patients' characteristics and effectiveness
outcomes.
Findings:We identiﬁed three types of treatment response trajectories: ‘gradual responders’ (GR; 3576 patients,
91·7%) had a baseline mean DAS28 of 4·1 and progressive improvement over time; ‘rapid responders’ (RR;
219 patients, 5·6%) had higher baseline DAS28 and rapid improvement in disease activity; ‘inadequate re-
sponders’ (IR; 103 patients, 2·6%) had high DAS28 at baseline (5·1) and progressive worsening in disease activ-
ity. They were similar in baseline characteristics. Drug discontinuation for ineffectiveness was shorter among
inadequate responders (p = 0.03), and EULAR good or moderate responses at 1 year was much higher among
‘rapid responders’ (p b 0.001).
Interpretation: Clinical information and baseline clinical characteristics do not allow a reliable prediction ofwhich
trajectory the patients will follow after bDMARD initiation.University Ho
ourvoisier).
. This is an op© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Response rate1. Introduction
The effect of disease modifying antirheumatic drugs (DMARDs) in
rheumatoid arthritis (RA) on disease activity is generally presented
using population means (Combe et al., 2015; Gabay et al., 2015;
Littlejohn et al., 2015). The use of biologic DMARDs (bDMARD) has rev-
olutionized the therapy of severe RA (Sanmarti et al., 2015). However,spital of Geneva,
en access article underthe response to treatment is heterogeneous, both to cDMARDs (Aga et
al., 2015), and to the various bDMARD agents (Kiely, 2015). As a
major aim in the new era of precision medicine is to make anti-rheu-
matic therapy more personalized, identifying and predicting distinct
treatment responses trajectories to DMARDs has major implications
for clinical practice. Studies (range n: 568–2752) focused on identifying
types of patients with similar evolutions in disease activity (Siemons et
al., 2014), physical activity (Demmelmaier et al., 2016), functional lim-
itation (Norton et al., 2013), or psychological distress (Norton et al.,
2011) and found subsets of patients with less favorable trajectories.
The identiﬁcation of predictors of response type trajectories couldthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Class-speciﬁc DAS28 trajectories based on observedmeans. Time horizonwas cut at
2 years to focus on the period with most available data.
303D.S. Courvoisier et al. / EBioMedicine 11 (2016) 302–306enable an early identiﬁcation of patients needing a distinct treatment
strategy.
In RA, disease activity measures are the main clinical outcome used
by practitioners to appraise the evolution of RA (Finckh et al., 2007),
to modify and adapt treatment, and to determine if patients have
reached a state of low disease activity (Inoue et al., 2007) or remission
(Mohammed et al., 2015). The Disease Activity Score based on 28 joints
(DAS28) is a well-established instrument to assess disease activity
(Prevoo et al., 1995).
A study of early RA patients (Siemons et al., 2014) (n= 568) found
three types of trajectories during theﬁrst year after treatment initiation:
themost frequent type (82·6% of patients)was a good responder group,
the second type (14·1%) comprised patients with a slower response to
treatment, and the third one was composed of a very small group
(3·3%) of patients who showed no improvement after 1 year. However,
the trajectories of disease activity in patients initiating a speciﬁc
bDMARD or in patients with established disease have not been studied.
The aim of this study was to identify different types of trajectories in
RA disease activity following the initiation of a new bDMARD and to ex-
amine the determinants of each responder type in a largemulti-national
observational cohort.
2. Materials and Methods
2.1. Study Design
This is a pooled analysis of data from nine national registries of RA
patients: ARTIS (Sweden), ATTRA (Czech Republic), DANBIO (Den-
mark), GISEA (Italy), NOR-DMARD (Norway), ORA (France), REUMA.PT
(Portugal), RHUMADATA (Canada), and SCQM (Switzerland), collected
from 2006 to 2015. Each of the registries was approved by the local
Ethics Committee and national guidelines for collection of informed
consent formbefore enrolment in the study in accordancewith theDec-
laration of Helsinki were followed. A more detailed description of the
registries is available elsewhere (Curtis et al., 2010; Finckh et al.,
2015). Inclusion criteria for this analysis were a diagnosis of RA, initia-
tion of ABA treatment and at least two assessments of DAS28. The pri-
mary outcome to model response trajectories was the disease activity
score based on 28 joints (DAS28) (Prevoo et al., 1995). Most registries
used DAS28-ESR; when not available, we used the DAS28-CRP instead.
All patients had either complete data for the DAS28-ESR or complete
data for the DAS28-CRP. Almost all registries had some patients with
missing DAS28-ESR data. The Italian registry, GISEA, was the only regis-
try with only DAS28-CRP data.
In addition to the DAS28, we extracted demographic variables, BMI,
smoking status, comorbidities, seropositivity according to rheumatoid
factor or anti-citrullinated protein antibodies (ACPAs), disease duration,
and disability as measured by the health assessment questionnaire
(HAQ).We also extracted information about treatment, including num-
ber of past biologics treatment, conventional DMARD (cDMARD) and
glucocorticosteroid therapy. We further computed ABA drug retention,
which integrates both drug effectiveness and tolerance, ABAdrug reten-
tion until stopping for ineffectiveness, reason for ABA discontinuation,
EULAR good or moderate response rate at 6 months, one year, and
two years (van Riel, 2014) corrected for drug discontinuation (Lundex)
(Kristensen et al., 2006). ABA drug retentionwas deﬁned as the time be-
tween drug initiation and last administration, plus one dispensation in-
terval. Patients lost to follow-up were censored at the last registered
visit.
2.2. Statistical Analysis
We used growth mixture models (GMM) to identify groups of pa-
tients with similar courses of treatment response, modeling time since
beginning of treatment as polynomials with a linear, quadratic and
cubic terms and derived empirically based trajectory subgroups. GMMare used to model unobserved types of evolution of disease activity
over time. GMM estimate groups of patients in which the trajectories
of DAS28 are similar within each trajectory type and different from
the trajectories in the other types (Reineke and Seddig, 2011). To deter-
mine the optimal number of types (also called latent classes in growth
mixture models terminology) of disease activity trajectories, we used
two information criteria (Akaike's information criteria, and Bayesian in-
formation criteria), with lower value indicating a better ﬁt of themodel
to the data.
We then examined the association of these groups with
demographic-, disease-, and treatment-related covariates, as well as
treatment effectiveness. We analyzed patients and disease characteris-
tics at treatment initiation using standard descriptive statistics and Fish-
er exact test for categorical variables or Wilcoxon rank sum test for
continuous variables. We ran a sensitivity analysis using probability-
weighted regression with weights based on posterior probability of
classiﬁcation in each trajectory group. Data are presented as means
(SD) or medians (interquartile ranges) depending on their distribution.
ABA drug retention was analyzed by the Kaplan Meier method. Given
the inherent differences between registries (Finckh et al., 2015), we
tested for effect modiﬁcation by registry using an interaction term be-
tween types of trajectories and national registry using a Cox proportion-
al hazardmodel. Analyseswere performed using R v3.2.4 (R foundation,
Vienna, Austria) and the lcmm package (Proust-Lima et al., 2015).
3. Results
A total of 3898 patients initiated ABA with a mean number of
3.94 DAS28 assessments. Follow-up time ranged from 1 month to
11.7 years. Trajectory analysis of the entire sample identiﬁed three
types of disease activity trajectories with low misclassiﬁcation (for
goodness of ﬁt indices, see Appendix 1). The largest group (3576 pa-
tients, 91·7%) can be labeled as the ‘gradual responders’ (GR) type,
with a mean DAS28 at baseline of 4·1 and a progressive improvement
over time. Fig. 1 presents the observed means for patients based on
assigned types of trajectories. Estimated mean trajectories were quite
similar (data not shown). The second group (219 patients, 5·6%) can
be described as the ‘rapid responders’ (RR) type, with higher DAS28
values at baseline, and a rapid improvement in disease activity. The
third group (103 patients, 2·6%) can be identiﬁed as ‘inadequate re-
sponders’ (IR) type, with higher DAS28 values at baseline, a short im-
provement during the ﬁrst 6 months, followed by a return to initial
disease activity level (for exact estimates of the DAS28 trajectories for
these three types of patients, see Appendix 2).
The three types were similar in age, sex, BMI distributions, disease
duration, and comorbidities (Table 1). ‘Gradual responders’ group had
Table 1
Characteristics and outcomes of the patients in each of the three trajectories' type.
‘Gradual
Responders’
‘Rapid
responders’
‘inadequate
responders’ p
Number of patients, n (%) 3576 (91.7%) 219 (5.6%) 103 (2.6%)
Time follow-up, years,
mean (SD)
2.0 (1.7) 2.2 (2.2) 2.1 (1.6)
Number of assessments,
mean (SD)
3.9 (3.9) 5.0 (4.9) 4.5 (2.4)
Age, years, mean (SD) 57.6 (13.0) 56.6 (12.7) 59.2 (12.6) 0.22
BMI, mean (SD) 25.8 (5.2) 26.1 (5.7) 28.1 (5.1) 0.10
Female, n (%) 2866 (80.1%) 187 (85.4%) 85 (82.5%) 0.14
Ever smoker, n (%) 582 (17.6%) 36 (17.2%) 14 (14.3%) 0.70
RF, n (%) 1521 (68.2%) 87 (64.4%) 47 (74.6%) 0.36
ACPA, n (%) 1165 (57.8%) 67 (51.5%) 41 (68.3%) 0.09
Disease duration, years,
mean (SD)
12.5 (9.9) 11.9 (9.1) 12.7 (9.0) 0.63
HAQ, mean (SD) 1.1 (0.7) 1.7 (0.6) 1.3 (0.8) b0.001
Tender joints at baseline,
mean (SD)
4.6 (5.3) 10.1 (7.1) 5.2 (6.6) b0.001
Swollen joints at baseline,
mean (SD)
3.1 (3.7) 7.3 (6.2) 4.4 (4.4) b0.001
ESR at baseline, mean (SD) 23.3 (18.6) 36.2 (28.1) 32.1 (22.0) b0.001
CRP at baseline, mean (SD) 9.5 (16.1) 20.3 (32.7) 11.7 (16.0) b0.001
Patient global assessment,
mean (SD)
47.5 (25.4) 61.5 (21.2) 45.0 (28.5) b0.001
DAS 28 at baseline, mean
(SD)
4.1 (1.0) 5.8 (1.1) 5.1 (1.1) b0.001
N. past biologics, median
[IQR]
1 [1; 2] 2 [1; 3] 2 [1; 3.5] b0.001
N past cDMARD, median
[IQR]
2 [1; 4] 2.5 [1; 4] 3 [1; 4] 0.03
Glucocorticoids at
baseline, n (%)
1773 (66.4%) 120 (67.4%) 66 (77.6%) 0.09
Comorbidities, n (%)
Metabolic disease 47 (1.3%) 4 (1.8%) 0 (0.0%) 0.49
CV disease 80 (2.2%) 6 (2.7%) 2 (1.9%) 0.86
Infectious disease 35 (1.0%) 1 (0.5%) 0 (0.0%) 0.69
Cancer 8 (0.2%) 0 (0.0%) 0 (0.0%) 1.00
ABA drug retentiona, years,
median[95% CI]
Overall 2.3 [2.1; 2.5] 1.6 [1.3; 3.0] 1.5 [1.4; 2.0] 0.11
Until ineffectiveness 4.7 [4.3; 5.1] 5.3 [2.6;−] 2.0 [1.7;−] 0.03
ABA discontinuation, n (%) 1981 (55.4%) 135 (61.6%) 78 (75.7%) b0.001
Reasons for
discontinuationb, n (%)
0.17
For adverse events 333 (16.8%) 12 (8.9%) 9 (11.5%)
For remission 19 (1.0%) 1 (0.7%) 0 (0.0%)
For other reasons 483 (24.4%) 31 (23.0%) 20 (25.6%)
For ineffectiveness 1146 (57.8%) 91 (67.4%) 49 (62.8%)
EULAR moderate or good
response
At 6 months, n (%) 645 (24.3) 31 (21.2) 31 (32.9) 0.11
At 6 months, % Lundex 21.8 16.3 32.9
At 1 year, n (%) 600 (30.8) 70 (66.0) 6 (8.2) b0.001
At 1 year, % Lundex 22.1 39.2 6.4
At 2 years, n(%) 647 (54.9) 68 (94.4) 3 (10.0) b0.001
At 2 years, % Lundex 29.8 46.1 3.9
Low disease activity
(DAS28 b 3.2)
At 6 months, N (%) 1120 (33.4) 15 (7.3) 16 (16.5) b0.001
At 1 year, N (%) 1256 (36.5) 36 (17.1) 1 (1.0) b0.001
At 2 years, N (%) 1433 (41.3) 54 (25.7) 1 (1.0) b0.001
a Estimated using Kaplan-Meier estimation.
b Other reasons include discontinuation due to pregnancy, surgery, and missing infor-
mation on the speciﬁc reason for drug discontinuation.
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Fig. 2. Boxplots of DAS28 values at baseline for the three types of trajectories.
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p b 0·001), and less previous treatment failures with cDMARDs and
bDMARDs. Groups differed in mean DAS28 at baseline (p b 0·001),
with ‘gradual responders’ generally presenting lower disease activity
at baseline. However, these differences were not the main determinantof group membership since the variability of DAS28 at baseline was
large, and there was a large overlap of DAS28 values between groups
(Fig. 2). Groups also differed in the components of the DAS28 score
(i.e., tender joints, swollen joints, ESR or CRP, and patient global assess-
ment). The sensitivity analysis using probability-weighted regression
accounting for uncertainty in classiﬁcation of patients into three groups
found similar results. In particular, signiﬁcant and non-signiﬁcant re-
sults remained the same.
ABA overall drug retention time was similar across all groups (p=
0·11). However, as could be expected, ABA drug retention until discon-
tinuation for ineffectiveness was much shorter among ‘inadequate re-
sponders’ (median time in years: GR, 4·7, RR: 5·3, IR: 2·0, p = 0·03).
The proportion of patients with EULAR good or moderate response
rate (Lundex corrected) at 1 year was higher among ‘rapid responders’
(GR: 22·1%, RR: 39·2%, IR: 6·4%).
4. Discussion
Safety and efﬁcacy of ABA in early and established RA has been dem-
onstrated in several studies, using population means or – one could say
– a single trajectory (Westhovens et al., 2009, 2014; Kremer et al., 2014;
Schiff et al., 2011, 2014). The present study focused on trajectory analy-
ses of disease activity following the initiation of ABA, using growthmix-
ture modeling to identify subgroups with similar response patterns.
This study, which is a collaboration of nine national registries, is the
ﬁrst to analyze trajectories of disease activity in patients with
established RA. Analysis of the entire sample identiﬁed three types of
disease activity trajectories: a larger group of ‘gradual responders’
(91·7%), who improved gradually over time; a group of ‘rapid re-
sponders’ (5·6%), who started with a high DAS28 at baseline and im-
proved quickly; and a smaller group of ‘inadequate responders’
(2·6%), who had a stable and relatively high disease activity over the
ﬁrst two years. Overall, socio-demographic and clinical characteristics
at baselinewere not strongly associatedwith future trajectory of disease
activity after ABA treatment initiation. The importance of identifying
these trajectories is reﬂected in the close association between clinical ef-
fectiveness and type of disease activity trajectory: The ‘inadequate re-
sponders’ discontinued ABA due to ineffectiveness much earlier
compared to gradual and rapid responders. Furthermore, EULAR mod-
erate or good response at 1 year was reached by almost none of the
“inadequate responders”, compared to more than a third of the ‘rapid
responders’.
Similarly to studies that examined disease activity trajectories in
early RA (Barnabe et al., 2015; Siemons et al., 2014), we identiﬁed a
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305D.S. Courvoisier et al. / EBioMedicine 11 (2016) 302–306large group of gradual responders and a small group of rapid re-
sponders. However, the present analysis also detected one group that
displayed no improvement of their disease activity over time. The differ-
ences in ﬁndings could be due to study population or to the smaller
sample size of previous studies. Whereas other studies focused on
early RA patients on their ﬁrst DMARD treatment, our analysis included
more treatment resistant patients, often initiating a second or third line
treatment, who often had long disease duration. In this difﬁcult to treat
patient group, it is not surprising to ﬁnd inadequate responders, a sub-
groupprobably composed of both primary non-responders and patients
with secondary failures to this biologic agent. It is also possible that the
smaller sample size and limited follow-up of other studies did not allow
the detection of small trajectory subgroups.
In general, the patients in the three trajectory types could not be
separated by baseline characteristics, except for higher disease activity
and functional disability at baseline among rapid responders. This ﬁnd-
ing is in linewith previous studies of patientswith established RA show-
ing that high DAS28 (Narvaez et al., 2016) and high HAQ score at
baseline are associated with good response to bDMARD at 3 months
(Kristensen et al., 2008). In contrast, studies of patients with early RA
(i.e., with less chronicity) described a group of rapid responders with
a lower DAS 28 at baseline, and found that patients' trajectory types dif-
fered in socio-demographic characteristics (e.g., sex, race, education)
(Barnabe et al., 2015). The discrepancies in ﬁndings may be explained
by differences in study population.
Much research is currently directed at identifying biomarkers to pre-
dict response and move towards personalized medicine; however no
biomarkers have currently reached a level of discrimination to allow
their use in clinical practice. Seropositivity for rheumatoid factor or
anti-CCP antibodies has been consistently associatedwith a better effec-
tiveness of ABA (Gottenberg et al., 2016), butwere not associatedwith a
speciﬁc disease activity trajectory in this analysis. Clinical effectiveness
outcomes strongly differed between trajectories' types, in linewith pre-
vious studies of disease activity or disability trajectories over time, in
which type of trajectories was associated with mortality (Norton et al.,
2013), remission (Siemons et al., 2014), or radiographic progression
(Barnabe et al., 2015).
A limitation of this study is the observational nature of the data with
the potential bias generated from attrition. In addition, unmeasured
baseline characteristics, such as socioeconomic factors, may be associat-
ed with disease trajectories (Finckh et al., 2015). Another limitation is
that DAS28 is a composite score, and the trajectories found in this
study may not correspond to trajectories of the underlying scores. The
strengths of this study include the large number of patients treated in
a real-life setting, resulting from an international collaboration that
allowed a pooled analysis of nine RA registries.
In conclusion, after ABA treatment initiation, different types of re-
sponders to treatment were identiﬁed: gradual, rapid and inadequate
response groups, with differing drug discontinuation and response
rates. However, clinical information such as seropositivity or disease du-
ration, and baseline characteristics, do not allow to predict reliably the
trajectory a patient will follow after ABA initiation. Other predictors of
responder types should be explored to support clinical decisionmaking.
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ﬁnal manuscript.Appendix 1. Goodness-of-ﬁt statistics for growth mixture modelingModel AIC BICPercentage of total
sampleType
1Type
2Type
3Type
41. 1 class, random
intercept46,626.4 46,664.1 1002. 1 class, random slope 46,424.0 46,467.8 100
3. 2 classes, random slope 46,269.5 46,344.7 80.2 19.8
4. 3 classes, random slope 46,163.0 46,269.6 91.7 5.6 2.6
5. 4 classes, random slope 52,549.8 52,713.0 82.8 11.1 4.5 1.6MFor M4, Type 1 (Gradual responders), Type 2 (rapid responders), Type 3 (inadequate
responders).
Posterior classiﬁcation was 0.77% in Type 1, 0.81% in Type 2, and 0.94% in Type 3.
Appendix 2. Estimates of best-ﬁtting growth mixture modelCoefﬁcient p 95% CIradual responders
tercept 4.06 b0.001 3.92; 4.20
me −0.69 b0.001 −0.88;−0.50
me2 0.28 b0.001 0.19; 0.37
me3 −0.03 b0.001 −0.05;−0.02apid responders
tercept 5.83 b0.001 5.47; 6.34
me −2.63 b0.001 −3.32;−1.94
me2 0.81 b0.001 0.47; 1.15
me3 −0.08 b0.001 −0.12;−0.3adequate responders
tercept 5.14 b0.001 4,53; 5.75
me 3.68 b0.001 2.46; 4.90
me2 −1.51 b0.001 −2.09;−0.93
me3 0.17 b0.001 0.09; 0.25TiReferences
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